Embecta Corp./$EMBC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Ticker

$EMBC
Primary listing

Industry

Health Care Equipment & Supplies

Employees

2,100

ISIN

US29082K1051

Embecta Corp. Metrics

BasicAdvanced
$606M
11.62
$0.89
1.19
$0.60
5.79%

What the Analysts think about Embecta Corp.

Analyst ratings (Buy, Hold, Sell) for Embecta Corp. stock.

Bulls say / Bears say

Embecta Corp. reported earnings per share of $0.65 for the quarter ended December 2024, surpassing the consensus estimate of $0.45 by $0.20, marking a 44.44% earnings surprise. (nasdaq.com)
The company has consistently exceeded consensus EPS estimates over the last four quarters, indicating strong operational performance. (nasdaq.com)
Embecta's revenue for the quarter ended December 2024 was $261.9 million, surpassing the consensus estimate by 2.02%, reflecting robust sales performance. (nasdaq.com)
Embecta's stock has declined approximately 11.9% since the beginning of the year, underperforming the S&P 500's gain of 3.1%, which may indicate investor concerns. (nasdaq.com)
The Medical Services industry, to which Embecta belongs, is currently ranked in the bottom 34% of over 250 industries, suggesting potential sector-wide challenges. (nasdaq.com)
Embecta's net income for the trailing twelve months is $52.80 million, resulting in a relatively low net profit margin, which could raise concerns about profitability. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

Embecta Corp. Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Embecta Corp. Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EMBC

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs